Pfizer today reported its antidepressant Pristiq (desvenlafaxine succinate extended release) in adolescents (7-17 years) with severe depression fail in clinical trials groups, and no significant improvement compared to placebo. This test a total of 363 patient involvement, of which 30 per cent of children aged 7-11. Test consists of three arms, namely the placebo, low dose (equivalent to an adult body weight equivalent to 25 mg daily) and high dose (equivalent to an adult body weight equivalent to 35 mg per day), there was no statistical difference between the results of the efficacy of the three groups.
Pristiq is original Wyeth products, Wyeth was acquired after 2009 became a member of the Pfizer Pfizer product lines. This product has been listed in 2008, but then there are some strings attached. One of the conditions is that Wyeth must follow the requirements of the Equality Act Youth Research do teenagers efficacy in clinical trials. In June this year, another adolescent patients in clinical trials of Pristiq also failed to improve symptoms better than placebo.
Venlafaxine is the first serotonin - norepinephrine reuptake inhibitors, and Prozac but regardless of the molecular structure or mechanism are very similar. Venlafaxine is one of Wyeth's flagship product, so the patent expired in 2010 have developed a new generation product Wyeth Pristiq. Pristiq is the active metabolite of venlafaxine (at least one Class A), so theoretically venlafaxine similar effect. A selling point is the Pristiq than venlafaxine easy to use, because the latter have to have a dose-climbing process. But Pristiq even in clinical trials in adults also general effect, more improvement than placebo only 2-3 points Hamilton index, and high-dose (100 mg) effect disappears. This dose-response relationship, although not impossible, but how much reliability doubtful efficacy.
In view of the above information Pristiq invalid in adolescent patients is not too unexpected. Adolescents and adults are quite different brain, liver and kidney metabolism is also more active, and there are some unknown factors now make many very reliable efficacy in adult drugs among adolescents is invalid. One theory is that these drugs are used to optimize adult animal model, so the success rate is higher than in adult children. But even these animal models of disease for adults is also very unreliable, I highly doubt with minor animal model can significantly improve the success rate of depression in adolescents drugs. A surprising data is that this experiment, 30% of patients are children 7-11 years of age. Age is so small it is unfortunately suffering from severe depression.
CNS field to extend the product with the active metabolite of life is quite common, because there is no reliable way to optimize. Although there is no venlafaxine Pristiq brilliant sales but also a sort of a small product. Today, the results of this test basically blocked the youth market Pristiq entering this road.
( Bolise Co., Ltd. http://www.chemicalspharm.com/ )
2015年12月22日星期二
4-AcO-MiPT describes the role and composition
Product name:4-AcO-MiPT
CAS:92292-84-7
Molecular Formula:C14H18N2O2
Molecular Weight:246.3g/mol
Description:The purity of this product is 99.8%.It is white powder and crystal.
Would like to ask specific details, please click here Email:sales@chemicalspharm.com
Elocalcitol describes the role and composition
Product name:Elocalcitol
CAS:199798-84-0
Molecular Formula:C29H43FO2
Formula Weight:442.65g/mol
Description:Elocalcitol is a vitamin D receptor agonist inhibiting Rho kinase signaling in rat and human bladder.It is an analogue of calcitriol that possesses the desirable properties of calcitriol but does not cause hypercalcemia.
Would like to ask specific details, please click here Email:sales@chemicalspharm.com
Cure for Alzheimer's disease! Clinton appealed to invest $ 2 billion
On Tuesday, Democratic presidential candidate Hillary • Clinton announced a program to promote Alzheimer's treatment plan, and seek to completely cure the disease by 2025, including specific measures to increase the disease and its related disorders research grants and so on.
According to Reuters, Clinton called for the establishment of a $ 2 billion per year and ten-year study of long-term investment plan, she said in a statement, said the government should help those afflicted by the disease of millions of families, increased investment in research to effective prevention and treatment of this disease, and to seek to achieve by 2025 a long-term goal of a complete cure of the disease.
Alzheimer's disease is an irreversible, progressive brain disease, is the most common type of dementia, accounting for 60-80% of all dementia cases. Alzheimer's disease will continue to be the most important public health challenges facing the United States, an estimated 5 million Americans over age 65 suffer from Alzheimer's disease, which is the US National Institute of Aging (National Institute on Aging) the sixth leading cause of death mentioned.
In the United States each year with Alzheimer's disease is directly related expenditures reached $ 203 billion, if the impact of the disease progression, delay disability-related aspects of dementia do not make a difference, by 2050, this figure is expected to increase to 10,000 One hundred million U.S. dollars. Hillary Clinton's campaign team noted that aggressive treatment of this disease is an effective way to help the government reduce the health insurance plans and health insurance burden.
According to Reuters, Clinton called for the establishment of a $ 2 billion per year and ten-year study of long-term investment plan, she said in a statement, said the government should help those afflicted by the disease of millions of families, increased investment in research to effective prevention and treatment of this disease, and to seek to achieve by 2025 a long-term goal of a complete cure of the disease.
Alzheimer's disease is an irreversible, progressive brain disease, is the most common type of dementia, accounting for 60-80% of all dementia cases. Alzheimer's disease will continue to be the most important public health challenges facing the United States, an estimated 5 million Americans over age 65 suffer from Alzheimer's disease, which is the US National Institute of Aging (National Institute on Aging) the sixth leading cause of death mentioned.
In the United States each year with Alzheimer's disease is directly related expenditures reached $ 203 billion, if the impact of the disease progression, delay disability-related aspects of dementia do not make a difference, by 2050, this figure is expected to increase to 10,000 One hundred million U.S. dollars. Hillary Clinton's campaign team noted that aggressive treatment of this disease is an effective way to help the government reduce the health insurance plans and health insurance burden.
2015年12月21日星期一
o-Chlorobenzalmalononitrile
Product name:o-Chlorobenzalmalononitrile
CAS: 2698-41-1
Molecular Formula:C10H5ClN2
Formula Weight: 188.61
Description:
Melting point:95 ºC
Boiling point:310-315 ºC
Flash point:148 ºC
Density:1.296 g/cm3
Chemical property:white crystalline solid with a peppery smell
Storage:In ventilate,cool and dry places.
from:http://www.acridine-raw-material.com/products/o-Chlorobenzalmalononitrile/
Bromo-DragonFLY for sale
Product name:Bromo-DragonFLY
CAS:502759-67-3
Molecular Formula:C13H12BrNO2
Molecular Weight:294.14g/mol
Description:Bromo-DragonFLY is a psychedelic hallucinogenic drug related to the phenethylamine family. Bromo-DragonFLY is considered an extremely potent hallucinogen, only slightly less potent than LSD with a normal dose in the region of 200 μg to 800 μg, and it has an extremely long duration of action up to several days.The hallucinogenic effect of bromo-DragonFLY is mediated by its agonist activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptors, and is most accurately described as a non-subtype selective 5-HT2 agonist, as it is actually twice as potent an agonist for 5-HT2C receptors as for 5-HT2A, as well as being less than 5x selective for 5-HT2A over 5-HT2B.
Would like to ask specific details, please click here Email:sales@chemicalspharm.com
Amazing! Eating fish help burn fat?
A recent study found that fish oil can be stored fat cells into fat-burning cells, which may help curb weight gain in middle-aged. Research results were published in international journals scientific reports.
The researchers explained that fish oil can activate receptors in the digestive tract, activating the sympathetic nervous system, thereby inducing fat cells metabolize fat.
Not all fat tissue to store fat. White fat cells store fat can help maintain energy supply, while brown fat cells are primarily responsible for the metabolism of fat to maintain normal body temperature. Brown fat cells in the baby's body is relatively abundant, but decreased with age, most of adulthood brown fat will disappear.
Another fat cells - beige fat cells - a type of fat cells in humans and mice recently found, studies have shown fat cells beige brown fat cells have a similar function, such cells will increase with age growth reduction, without these burning fat cells, the fat will be piled up for decades and will not be consumed.
In this study, researchers for the intake of a particular type of food is to increase the number of beige fat cells were studied. The authors say: "We know from previous studies in some of the fish oil has many health benefits, including preventing the accumulation of fat, so we are on whether fish oil intake and beige fat increases an association has been studied."
The researchers carried out a group of mice fed the control diet, while another group on the basis of the control diet added fish oil, results showed that compared to the control group did not eat fish oil, fish oil 5% weight loss in mice 10%, fat content decreased by 15% to 25%. The researchers also found that when the sympathetic activation within white adipose tissue will form a new beige fat cells, increased fat consumption.
The researchers explained that fish oil can activate receptors in the digestive tract, activating the sympathetic nervous system, thereby inducing fat cells metabolize fat.
Not all fat tissue to store fat. White fat cells store fat can help maintain energy supply, while brown fat cells are primarily responsible for the metabolism of fat to maintain normal body temperature. Brown fat cells in the baby's body is relatively abundant, but decreased with age, most of adulthood brown fat will disappear.
Another fat cells - beige fat cells - a type of fat cells in humans and mice recently found, studies have shown fat cells beige brown fat cells have a similar function, such cells will increase with age growth reduction, without these burning fat cells, the fat will be piled up for decades and will not be consumed.
In this study, researchers for the intake of a particular type of food is to increase the number of beige fat cells were studied. The authors say: "We know from previous studies in some of the fish oil has many health benefits, including preventing the accumulation of fat, so we are on whether fish oil intake and beige fat increases an association has been studied."
The researchers carried out a group of mice fed the control diet, while another group on the basis of the control diet added fish oil, results showed that compared to the control group did not eat fish oil, fish oil 5% weight loss in mice 10%, fat content decreased by 15% to 25%. The researchers also found that when the sympathetic activation within white adipose tissue will form a new beige fat cells, increased fat consumption.
订阅：
博文 (Atom)